Early ART to Limit Infection and Establishment of Reservoir
Status:
Active, not recruiting
Trial end date:
2023-09-08
Target enrollment:
Participant gender:
Summary
The study is being done to:
- start ART early in those recently or acutely infected with HIV-1
- see how starting ART as soon as the infection is found affects the amount of HIV-1 in
blood and how well the body fights the HIV-1 infection
- look at the amount of HIV-1 DNA (genetic material for HIV-1) seen in CD4+ T-cells
(infection-fighting cells in blood) after 48 weeks of ART
- see how early treatment for HIV affects the numbers of HIV-1 infection fighting cells
(CD4+ and CD8+ T-cells) in blood
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)